%0 Journal Article
%T Does Comorbidity Increase the Risk of Dengue Hemorrhagic Fever and Dengue Shock Syndrome?
%A Shahid Mahmood
%A Saadia Hafeez
%A Hiba Nabeel
%A Urooj Zahra
%A Hammad Nazeer
%J ISRN Tropical Medicine
%D 2013
%R 10.1155/2013/139273
%X Background. Dengue fever is an emerging public health problem in Pakistan. The aim of this study was to determine the relationship between comorbid conditions in individuals suffering from dengue fever and the development of dengue hemorrhagic fever or dengue shock syndrome. Methods. In this age- and sex-matched case control study, total of 132 cases of dengue hemorrhagic fever/dengue shock syndrome and 249 randomly selected controls were recruited from two major teaching hospitals of Lahore, Pakistan. A semistructured questionnaire was used to collect data through interview and by reviewing clinical records. SPSS version 18 was utilized for statistical analysis including conditional logistic regression. Results. Odds of developing dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS) among diabetics are higher than in controls, but this association was not found statistically significant (OR. 1.26; 95% CI. 0.78¨C2.03; ). Similarly, no association was observed in individuals suffering from hypertension (OR. 0.93; 95% CI. 0.57¨C1.49; ). Odds of developing DHF and DSS were higher for bronchial asthma (adjusted OR. 1.34) and pulmonary tuberculosis (adjusted OR. 1.41); however P values were insignificant. Conclusion. Presence of diabetes mellitus, hypertension, ischemic heart disease and bronchial asthma among patients contracted dengue fever will not increase the risk of dengue hemorrhagic fever and dengue shock syndrome. 1. Background Dengue fever is an emerging public health problem prevalent mostly in tropical and subtropical regions of the world. It is an arbovirus infection transmitted through Aedes aegypti and Aedes albopictus mosquito species. Four dengue virus serotypes (DENV-1, DENV-2, DENV-3, and DENV-4) have yet been identified and are responsible for most of the clinical manifestations, ranging from asymptomatic disease to symptomatic dengue fever (DF) and dengue hemorrhagic fever (DHF). In majority of patients, infection is self-limiting, but in small proportions, the resultant dengue shock syndrome (DSS) may increase morbidity and mortality. Infection with one serotype does not give protection against other dengue viruses, yet sequential infections increase the risk of developing dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS) [1, 2]. Dengue is endemic in many Southeast Asian countries and Western pacific region [2]. About 2.5 billion people (40% of worldĄŻs population) are at risk of dengue transmission. The World Health Organization (WHO) estimates that 50 to 100 million infections occur yearly, including 500,000 DHF
%U http://www.hindawi.com/journals/isrn.tropical.medicine/2013/139273/